Relative rate of developing inhibitory antibodies against factor VIII in severe hemophilia A patients receiving recombinant factor VIII products as compared to plasma-derived factor VIII products
| . | RR (95% CI) . |
|---|---|
| All patients* | N=322 |
| Crude relative rate | 1.0 (0.5-1.7) |
| Adjusted relative rate | 1.2 (0.7-2.1) |
| Exposure days on Beriate excluded | |
| Crude relative rate | 0.9 (0.5-1.6) |
| Adjusted relative rate | 1.1 (0.6-2.0) |
| Exposure days after switch of product excluded | |
| Crude relative rate | 1.3 (0.7-2.4) |
| Adjusted relative rate | 1.5 (0.8-3.0) |
| Beriate and postswitch exposure days excluded | |
| Crude relative rate | 1.3 (0.6-2.7) |
| Adjusted relative rate | 1.4 (0.6-2.9) |
| . | RR (95% CI) . |
|---|---|
| All patients* | N=322 |
| Crude relative rate | 1.0 (0.5-1.7) |
| Adjusted relative rate | 1.2 (0.7-2.1) |
| Exposure days on Beriate excluded | |
| Crude relative rate | 0.9 (0.5-1.6) |
| Adjusted relative rate | 1.1 (0.6-2.0) |
| Exposure days after switch of product excluded | |
| Crude relative rate | 1.3 (0.7-2.4) |
| Adjusted relative rate | 1.5 (0.8-3.0) |
| Beriate and postswitch exposure days excluded | |
| Crude relative rate | 1.3 (0.6-2.7) |
| Adjusted relative rate | 1.4 (0.6-2.9) |
For recombinant F VIII compared with plasma-derived products with high VWF content.
High von Willebrand factor concentration was defined as more than 0.01 IU VWF antigen per IU factor VIII antigen.
RR indicates relative rate; CI, confidence interval; and VWF, von Willebrand factor.